Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.655 -0.055 (-2.03%)
Streaming Delayed Price Updated: 11:33 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock. 
Via The Motley Fool
Topics Stocks
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter. 
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗
A patient, partnership-driven family office didn’t wait for fundamentals to break before walking away, and that timing may matter more than the sale itself. 
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Allogene Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones. 
Via Benzinga
News headline image
The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance
Washington D.C. – December 4, 2025 – A persistent and increasingly vocal debate continues to plague the halls of Congress, centering on allegations that elected officials are leveraging their unique... 
Via MarketMinute
Topics Bonds ETFs World Trade
News headline image
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress ↗
Allogene Therapeutics beat Q3 2025 earnings estimates with a narrower loss and reaffirmed its cash runway into 2027. The biotech also reported progress on its allogeneic CAR T pipeline. 
Via Chartmill
Topics Earnings
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics ↗
 
Via Benzinga
News headline image
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Allogene Q2 Cash Tops $300 Million ↗
Via The Motley Fool
News headline image
Allogene Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly ↗
Allogene Therapeutics reported a Q2 2025 net loss of $0.23 per share, beating estimates, with revenue at $0. Shares rose 1% post-earnings as investors focused on cost discipline and clinical progress. 
Via Chartmill
News headline image
A Look at Allogene Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Allogene Resets Clinical Course After Patient Death In Lymphoma Study ↗
Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating its clinical approach. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise ↗
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy. 
Via Stocktwits
News headline image
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 13, 2025 ↗
 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Friday's session: top gainers and losers ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
What's going on in today's session ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Friday's session: gap up and gap down stocks ↗
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges ↗
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.